[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 23, Issue 6 (1-2019) ::
__Armaghane Danesh__ 2019, 23(6): 683-693 Back to browse issues page
The Effect of Vascular Endothelial Growth Factor Antagonist Peptide (VGB4) on Breast Tumor Growth Suppression in Vivo
M Farzaneh Behelgardi1 , S Zahri1 , F Mashayekhi2 , SM Asghari 3
1- Department of Biology, University of Mohaghegh Ardabili, Ardabil, Iran
2- Department of Biology, University of Guilan, Guilan, Iran
3- Department of Biology, University of Guilan, Guilan, Iran , sm_asghari@guilan.ac.ir
Abstract:   (2326 Views)
Background & aim: The vascular endothelial growth factor of the tumor, which binds to its receptors at the level of endothelial cells, plays an important role in vascular permeability and tumor angiogenesis. In the present study, a vascular endothelial cell growth factor antagonist peptide (VEGF) was designed with the goal of inhibiting the desired peptide (VGB4) interfering with endothelial growth factor receptors in its receptors, thereby inhibiting the signaling pathways angiogenesis.
Methods: In the present experimental study, 42 female Balb / C mice (4 to 6 weeks old) with an average weight of 20 grams were used. Tissue cell line 4T1 was used to model breast cancer. It turned out after subcutaneous transplantation of mammary tumors in animals, daily intraperitoneal injection of different doses of VGB4 peptide (10, 5, 2.5, 1, 0.25 mg / kg) for 14 days, and the antitumor potential of different peptide concentrations during the injection period compared to the control was statistically analyzed. Data were analyzed by ANOVA and Duncan tests.
Results: Increasing the doses of peptide reduced the tumor growth in treated groups, but no significant inhibitory effect was seen on tumor growth by increasing the dose from 5 mg / kg to 10 mg / kg. Therefore, the dose of 5 mg / kg is the best anti-tumor dose of the VGB4 peptide.                                                                                                                                
Conclusion: VGB4 peptide had a significant inhibitory effect on the growth of breast cancer carcinoma of the 4T1 cell line. Due to the effects of VIT4 antitumor, it may be possible to use this peptide for cancer treatment in the future.
Keywords: Angiogenesis, Peptide, Vascular Endothelial Growth Factor, Breast Cancer
Full-Text [PDF 318 kb]   (443 Downloads)    
Type of Study: Research | Subject: Biochemistry
Received: 2018/07/17 | Accepted: 2018/12/25 | Published: 2018/12/25
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farzaneh Behelgardi M, Zahri S, Mashayekhi F, Asghari S. The Effect of Vascular Endothelial Growth Factor Antagonist Peptide (VGB4) on Breast Tumor Growth Suppression in Vivo. Armaghane danesh. 2019; 23 (6) :683-693
URL: http://armaghanj.yums.ac.ir/article-1-2248-en.html

Volume 23, Issue 6 (1-2019) Back to browse issues page
ارمغان دانش Armaghane danesh
Persian site map - English site map - Created in 0.03 seconds with 30 queries by YEKTAWEB 4311